Delcath (DCTH): חובות להיוון בספרים

The market capitalization trend for Delcath Systems, Inc. (DCTH) reflects dynamics based on the development of blood filtration systems for localized liver treatment, which reduces overall therapy toxicity. Production stability is ensured through the creation of component reserves, eliminating assembly downtime. The current metric stands at 0.02, while the business relies on the closed CHEMOSAT ecosystem, which strictly binds clinics to brand regulations.

This ratio determines the company's degree of dependence on borrowed funds by comparing total liabilities to equity to assess default risks and the efficiency of financial leverage. By analyzing the dynamic trend of financial leverage on the balance sheet, an investor can see how Delcath Systems, Inc. (DCTH) balances its debt load against the resources required for the commercialization of liver cancer treatment systems during the regulatory approval period.